This multidisciplinary research project will test the novel hypothesis that Dll4-triggered signaling contributes to the pathogenesis of atherosclerosis. We will focus on macrophage-derived proteolytic activity, the key feature typical of arterial remodeling associated with the onset of acute coronary events. We previously reported that Dll4 (a ligand of Notch signaling) promotes expression or activation of pro-inflammatory factors (e.g., iNOS, NF-?B) in cultured macrophages. The role of Notch signaling is strictly cell-type- and context- dependent, and in vivo functions of the Notch pathway in macrophages remain unknown. Using mouse models, the present study will explore the role of the Dll4-Notch axis in activation of plaque macrophages and development of atherosclerosis.
Specific Aim 1 will examine whether Dll4 antibody administration attenuates macrophage activation and atherogenesis in Ldlr-/- mice. We will also use macrophage-targeted in vivo delivery of Dll4 siRNA to determine the relative contribution of macrophage Dll4.
Specific Aim 2 will address the role of Notch3 based on our data that suggested its pro-atherogenic role. In Notch3-transgenic and null mice to test the hypothesis that this Notch receptor promotes macrophage activation and athrogenesis. These complementary studies will offer novel mechanisms of macrophage activation and atherosclerosis, and will also provide proof of concept that the Dll4-Notch3 pathway can be a therapeutic target for atherosclerosis, its complications, and other vascular diseases.
Inflammation in coronary arteries triggers acute complications of atherosclerosis (e.g., heart attack). However, the mechanism for arterial inflammation remains incompletely understood. We previously used cell culture systems that Delta-like 4 (Dll4) triggers inflammation. The present study will perform mouse experiments to dissect the new mechanisms of inflammation and atherosclerosis. The potential outcomes will offer new therapeutic targets for vascular diseases and contribute to preventive cardiovascular medicine.
|Decano, Julius L; Aikawa, Masanori (2018) Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease. Front Cardiovasc Med 5:97|
|Lee, Lang Ho; Andraski, Allison B; Pieper, Brett et al. (2017) Automation of PRM-dependent D3-Leu tracer enrichment in HDL to study the metabolism of apoA-I, LCAT and other apolipoproteins. Proteomics 17:|
|Singh, Sasha A; Aikawa, Masanori (2017) Unbiased and targeted mass spectrometry for the HDL proteome. Curr Opin Lipidol 28:68-77|
|Goettsch, Claudia; Iwata, Hiroshi; Hutcheson, Joshua D et al. (2017) Serum Sortilin Associates With Aortic Calcification and Cardiovascular Risk in Men. Arterioscler Thromb Vasc Biol 37:1005-1011|
|Singh, Sasha A; Andraski, Allison B; Pieper, Brett et al. (2016) Multiple apolipoprotein kinetics measured in human HDL by high-resolution/accurate mass parallel reaction monitoring. J Lipid Res 57:714-28|
|Goettsch, Claudia; Hutcheson, Joshua D; Hagita, Sumihiko et al. (2016) A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modification. Atherosclerosis 251:109-118|
|Iwata, Hiroshi; Goettsch, Claudia; Sharma, Amitabh et al. (2016) PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat Commun 7:12849|
|Nakano, Toshiaki; Fukuda, Daiju; Koga, Jun-Ichiro et al. (2016) Delta-Like Ligand 4-Notch Signaling in Macrophage Activation. Arterioscler Thromb Vasc Biol 36:2038-47|
|Goettsch, Claudia; Hutcheson, Joshua D; Aikawa, Masanori et al. (2016) Sortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Invest 126:1323-36|
|Lu, Hong; Aikawa, Masanori (2015) Many faces of matrix metalloproteinases in aortic aneurysms. Arterioscler Thromb Vasc Biol 35:752-4|
Showing the most recent 10 out of 21 publications